[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-disorder-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-disorder-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,53,81,108,136,169,206,231,262,286,316,342,370,390,420,447,471,502,528],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100627110","start-cpap-therapy-in-obstructive-sleep-apnea-patients-after-atrial-fibrillation-ablation-100627110",false,"NCT07444372","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation: A Multicenter, Open-label, Randomized Clinical Trial","STOP-AFib","Inclusion Criteria:\n\nPatients must meet all of the following conditions to be eligible for the study:\n\n* Age 18-75 years.\n* Patients with persistent AF scheduled for first-time catheter ablation.\n* Diagnosed with OSA.\n* Able to tolerate CPAP therapy.\n* Capable of understanding and complying with the study protocol.\n* Willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n* Secondary AF.\n* Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).\n* Left ventricular ejection fraction \\\u003C 30%.\n* Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).\n* Pregnant or breastfeeding women.\n* History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.\n* History of stroke or transient ischemic attack within 6 months prior to screening.\n* Perioperative complications related to the ablation procedure occurring prior to randomization.\n* Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.\n* Life expectancy \\\u003C 1 year.\n* Central sleep apnea.\n* Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI \\> 30kg\u002Fm² and awake PaCO₂ \\> 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with \\> 1 episode of respiratory failure or hypercapnia.\n* Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.\n* Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.\n* Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.\n* Current participation in other drug or device trials.","ALL","18 Years","75 Years",{"count":21,"type":22},658,"ESTIMATED","INTERVENTIONAL",[25],"NA","Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.\n\nThis study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.\n\nParticipants will:\n\n* Be randomly assigned to either the CPAP group or the usual care group.\n* If in the CPAP group, use a CPAP device for 12 months.\n* Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months post-operation.\n* Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after their procedure.",[28,29,30,31,32,33],"Obstructive Sleep Apnea","Sleep Disorder (Disorder)","Atrial Fibrillation (AF)","Sleep Disordered Breathing (SDB)","Arrhythmia","Continuous Positive Airway Pressure",[28,33,35,36,37,38,39],"Atrial Fibrillation","Ablation of atrial fibrillation","Sleep Disordered Breathing","Clinical Trial","Catheter Ablation","RECRUITING","2026-06-14",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":44},"2026-05-12",{"date":48,"type":22},"2029-01-31",{"name":50,"class":51},"Beijing Anzhen Hospital","OTHER",27,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100643651","innovative-sleep-quality-analysis-software-compared-with-polysomnography-100643651","NCT07628959","Innovative Sleep Quality Analysis Software Compared With Polysomnography","Pilot Study of Innovative Sleep Quality Analysis Software Compared With Polysomnography","LUNA","Inclusion Criteria:\n\n* Adult patients aged over 18 years.\n* Patients affiliated with or beneficiaries of a social security system.\n* Patients capable of completing all aspects of the study.\n* Patients who have signed informed consent for participation in the study\n\nExclusion Criteria:\n\n* pregnancy\n* Patients suffering from an acute bacterial, fungal, or viral infection.\n* Patients unable to tolerate the placement of the PSG.\n* Patients with psychiatric disorders incompatible with the constraints associated with the need to spend two nights at the clinic.\n* restless legs syndrome\n* Presence of a cardiac pacemaker.\n* Cardiac arrhythmia problems (e.g., complete arrhythmia).\n* Known and treated sleep disorders (e.g., sleep apnea syndrome) or uncontrolled chronic insomnia.\n* Diagnosed dementia.\n* Simultaneous participation in other research studies.\n* Use of medications that could alter sleepiness, including:\n* Sedative-hypnotics.\n* Neuroleptics.\n* Antidepressants.\n* Anxiolytics.\n* H1 antihistamines.\n* Antiepileptics.\n* Opiates and opioid analgesics.\n* Patients under legal guardianship or curatorship.",{"count":62,"type":22},33,[25],"To diagnose sleep disorders, practitioners primarily use polysomnography (PSG), a precise but costly, cumbersome method that is limited to a single observation. This does not allow for longitudinal monitoring of sleep habits in real-world conditions. An alternative is offered with the C. Santé software receiving information from sensors installed on medical bed. This software analyzes cardiorespiratory parameters and sleep phases without disturbing the patient, enabling continuous and comfortable monitoring. A preliminary study aims to validate the reliability of the C. Santé software analysis, by comparing it to the PSG analysis, considered the gold standard.",[29],[67,68,69],"polysomnography","BCG","Sleep Disorders","NOT_YET_RECRUITING","2026-06-08",{"date":73,"type":44},"2026-06-10",{"date":75,"type":22},"2026-06",{"date":77,"type":22},"2026-12",{"name":79,"class":51},"Centre Hospitalier Universitaire de Saint Etienne",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":80},"100643255","sensory-and-behavioral-sleep-training-100643255","NCT07638605","Sensory and Behavioral Sleep Training","A Comparison of Sensory and Behavioral Sleep Training in Individuals With Sleep Problems","Inclusion Criteria:\n\n* Aged 20 to 55 years\n* Pittsburgh Sleep Quality Index global score of 5 or higher\n* Able to use a smartphone\n* Able to understand and speak Turkish\n* Willing to participate voluntarily and provide informed consent\n\nExclusion Criteria:\n\n* History of substance dependence\n* Presence of a chronic physical illness or a diagnosed psychiatric disorder\n* Regular medication use, particularly sleep-regulating medications, antidepressants, or similar medications that may affect sleep\n* Diagnosis of a sleep disorder, such as insomnia or sleep apnea\n* Mini-Mental State Examination score below 24\n* Regular meditation or similar mind-body practice for more than 15 minutes per day\n* Body mass index greater than 34.9 kg\u002Fm²\n* Previous participation in a sleep hygiene education program",true,"20 Years","55 Years",{"count":92,"type":22},54,[25],"Sleep problems may affect individuals' daily functioning, emotional well-being, cognitive performance, and quality of life. Non-pharmacological approaches, including sleep hygiene education, sensory-based strategies, and behavioral relaxation techniques, may help individuals develop healthier sleep routines. However, studies directly comparing sensory-based and behavioral approaches are limited.\n\nThe aim of this randomized controlled study is to compare the effects of sensory-based and behavioral sleep interventions in adults experiencing poor sleep quality. Participants are randomly assigned to one of three groups: a sleep hygiene education group, a sensory-based intervention group, or a behavioral intervention group. All participants receive a standardized six-week sleep hygiene education program. In addition, the sensory-based intervention group uses aromatherapy and pink noise, while the behavioral intervention group practices progressive muscle relaxation and diaphragmatic breathing exercises.\n\nParticipants are assessed before and after the six-week intervention period. The study examines changes in sleep quality and sleep-related behaviors, as well as anxiety, quality of life, activity-role balance, sensory processing characteristics, autonomic nervous system activity, and sleep parameters. The study is expected to provide information about the potential contribution of sensory-based and behavioral strategies to the management of sleep problems.",[29],[97,98,99],"sleep disorder","sensory-based","behavioral","2026-06-05",{"date":73,"type":44},{"date":103,"type":44},"2025-12-15",{"date":105,"type":22},"2026-07",{"name":107,"class":51},"Atlas University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":132,"leadSponsor":134,"locationsCount":80},"100638793","phase-2-electrophysiological-analysis-of-gamma-hydroxybutyrate-induced-sleep-in-intensive-care-patients-100638793","NCT07596342","Electrophysiological Analysis of Gamma-Hydroxybutyrate-induced Sleep in Intensive Care Patients","Electrophysiological Analysis of Gamma-Hydroxybutyrate-induced Sleep in Intensive Care Patients: A Pilot Double-Blind Randomized Controlled Trial","GAMMA-SLEEP","Inclusion Criteria:\n\n1. Aged 18 years or older\n2. Hospitalized in the ICU for more than 48 hours\n3. Informed consent obtained from the patient\n\nExclusion Criteria:\n\n1. Unstable patient\n2. Known allergy to Gamma-Hydroxybutyrate or any of the excipients\n3. Technical impossibility of performing polysomnography\n4. Childbearing or Positive pregnancy test for women of childbearing age or breastfeeding\n5. Patient who has already received the study treatment\n6. History of chronic alcoholism\n7. Uncontrolled epilepsy despite appropriate antiepileptic treatment\n8. Traumatic brain injury or neurological lesion at risk of epilepsy in the last month\n9. Severe hypertension: SBP \\> 180 mmHg despite antihypertensive treatment\n10. Hypokalemia \\\u003C 3.5 mmol\u002FL despite potassium supplementation\n11. Bradycardia due to intra-cardiac conduction disorders\n12. Obstructive sleep apnea syndrome\n13. Sodium restriction: Salt intake \\\u003C 3g\u002F24h\n14. Patients with known or suspected succinic semialdehyde dehydrogenase (SSADH) deficiency, given the risk of GHB accumulation due to impaired endogenous metabolism.\n15. Patients receiving barbiturates at inclusion\n16. Patients receiving opioids at inclusion for non-mechanically ventilated patient\n17. Patients presenting with hypernatraemia (sodium \\> 145 mmol\u002FL) or hyperchloraemia (chloride \\> 110 mmol\u002FL) at inclusion\n18. Patients with hepatic impairment (Child-Pugh B or C)\n19. Deep sedation defined by a RASS score \\\u003C -2\n20. Presence of mental confusion: Positive CAM-ICU\n21. Moribund patient or high likelihood of death within 48 hours\n22. Legal protection: guardianship, curatorship, or judicial protection\n23. Lack of social security or on AME (state medical aid)\n24. Participation in another interventional clinical trial related to the management of sleep disorders, delirium, or sedation in the ICU.",{"count":117,"type":22},24,[119],"PHASE2","In intensive care, sleep disturbances are extremely common and represent a major source of discomfort for patients. Restorative sleep is very limited. Beyond being the primary source of discomfort reported by patients, these sleep disturbances are associated with difficulties in weaning from mechanical ventilation, an increased risk of delirium, and potentially higher mortality. Traditional treatments artificially increase the total duration of sleep but lead to disrupted sleep architecture.\n\nGamma-hydroxybutyrate (GHB) is currently used for several sleep disorders, such as narcolepsy, due to its ability to increase restorative sleep. This medication has been used for years as a sedative in intensive care. Despite these potential benefits, the efficacy of GHB has never been evaluated for sleep disturbances in intensive care settings.\n\nThis study focuses on evaluating the effectiveness of intravenous Gamma-hydroxybutyrate (GHB) in the treatment of sleep disorders in intensive care.",[29,122],"Critical Care",[124,125,126,127],"Gamma-hydroxybutyrate","Sleep disorder","ICU","Slow-wave sleep","2026-05-20",{"date":130,"type":44},"2026-05-22",{"date":75,"type":22},{"date":133,"type":22},"2027-10",{"name":135,"class":51},"Assistance Publique - Hôpitaux de Paris",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":80},"100637038","sleep-stress-and-migraine---an-observational-and-training-study-100637038","NCT07573488","Sleep, Stress and Migraine - an Observational and Training Study","Migraine Sleep Study (MiSleepS) - The Role of Sleep and Stress as a Trigger in Migraine","MiSleepS","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years\n* Diagnosis of episodic migraine according to The International Classification of Headache Disorders (ICHD-3) criteria confirmed by our headache specialists\n* 4 to 14 headache days per month (mean value based on the 3 months prior to study enrollment)\n* Ability to give informed consent and to adhere to the study protocol\n* Sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes\n* Stable migraine medication regimen for the past 3 months and throughout the study period\n\nExclusion Criteria:\n\n* Diagnosis of sleep disorders that could interfere with the sleep intervention, such as obstructive sleep apnea with an apnea-hypopnea index (AHI) \\> 15, Restless Legs Syndrome, frequent (i.e. weekly) Non-rapid eye movement (NREM) sleep parasomnia, REM Behavior Disorder (RBD)\n* Current diagnosis of a psychiatric disorder that is inadequately treated or therapy-resistant and may interfere with study participation or adherence to study procedures (this includes, but is not limited to: schizophrenia, schizoaffective disorder, bipolar disorder (type I), post-traumatic stress disorder with active symptoms, or major depressive disorder with ongoing functional impairment despite treatment). Diagnosis must be confirmed by clinical history or treating physician.\n* Regular use of benzodiazepines and other central nervous system (CNS)-depressant substances (self-reported)\n* Concomitant steroid medication (self-reported)\n* Known or suspected alcohol, drug or medication abuse (i.e. \\> 0.5 l wine or 1 l beer per day)\n* Inability to follow the procedures of the study (e.g., due to language problems, cognitive deficits, instable home situation)\n* Concurrent participation in another study involving drug and behavioral interventions within 3 months prior to and during the present study, as well as participation in an ongoing study with data collection through SEMA3\n* Planned medical intervention of substantial relevance requiring hospitalization for more than 24 hours (e.g. surgery) during intervention (routine assessments, e.g. check-ups will be allowed)\n* Shift work with working during the night\n* Travelling more than 2 time zones in the last month before the observation or intervention periods or during the study\n* Persons who are pregnant or breastfeeding","65 Years",{"count":146,"type":22},80,[25],"The MiSleepS study investigates how sleep disturbances and stress are linked to migraine attacks. Participants wear a device called a WHOOP band, which tracks sleep and body signals, and answer brief daily questions via a smartphone app about their sleep, stress levels, and migraine symptoms. The goal is to identify personal patterns that may contribute to migraine. Based on these insights, participants receive individualized recommendations to improve their sleep and daily routines - aiming to reduce migraine attacks in the long term without medication. The study is conducted at the University Hospital Zurich and is aimed at adults with episodic migraine.",[150,29,151,152],"Migraine","Stress","Migraine in Adults",[154,155,156,157,158,159],"migraine","behavioral therapy","sleep hygiene","stress management","migraine triggers","non-medical prophylaxis","2026-05-03",{"date":162,"type":44},"2026-05-07",{"date":164,"type":22},"2026-05-18",{"date":166,"type":22},"2027-07-31",{"name":168,"class":51},"Susanne Wegener",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":188,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":205},"100615129","insight-insomnia-nightmares-and-sympathetic-hyperactivity-intervention-100615129","NCT07288593","INSIGHT: Insomnia, Nightmares, and Sympathetic Hyperactivity Intervention","Insomnia, Nightmares, and Sympathetic Hyperactivity Intervention in the warfiGHTer (INSIGHT)","INSIGHT","Inclusion Criteria:\n\n* Defense Enrollment Eligibility Reporting System (DEERS) Eligible\n* Current or former military service member\n* Able to read and understand English language without the use of an interpreter\n* Habitual bedtime between 9:00 PM and 1:00 AM\n* Aged 18-62 (inclusive)\n* Able to commit to study procedures\n\nExclusion Criteria:\n\n* Use of alpha or beta-receptor active medications or prescribed sleep aids in the last 3 months\n* Started use of SNRIs or SSRIs in the last 3 months\n* Pregnant\n* Receiving ongoing and extensive treatment for a new or acute psychiatric disorder within 90 days, other than routine follow-up and care\n* Starting concurrent evidence based psychiatric treatment within the past three months\n* Diagnosis of a serious medical condition (i.e., late-stage cancer or heart disease)\n* Routine night shift work in the past 3 months\n* Unstable neurological disease\u002Fautonomic disorders\u002F heart conditions\u002Fpsych\u002F sleep or other unstable disorder as determined by the Principal Investigator\u002FAssociate\n* Investigators determined by clinical interview by Mini international neuropsychiatric interview and medical health questionnaire\n* Excessive alcohol use as determined by the AUDIT-C (AUDIT-C \\> 3)\n* Started using any other medication (prescribed or over-the-counter) for the purpose of improving sleep in the last 90 days (e.g., barbiturates, benzodiazepines, melatonin, natural supplements and herbs, antidepressants, antihistamines, etc.)\n* Receiving treatment for substance use disorder within 90 days from the start of the study\n* Evidence of moderate or severe Obstructive Sleep Apnea (OSA): Determined by the STOP-BANG questionnaire: STOP-BANG greater than 5 Determined by EMR PSG records: moderate or severe OSA \\[apnea-hypopnea index (AHI)≥15\\]\n* Clinically significant suicidality as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)\n* Currently participating in other research studies for improving sleep\n* Currently participating in other research studies for improving PTSD\n* Currently in therapy for the primary purpose of improving sleep (e.g., CBT-I)\n* Currently undergoing other treatment to improve sleep (e.g., acupuncture)\n* History or diagnosis of any of the following sleep disorders: narcolepsy, shift-work disorder or circadian rhythm disorders\n* Prone to problems with venipuncture including fainting, hematoma, and infection\n* Moderate and high nicotine dependence based on the Fagerstrom Test for Nicotine Dependence (\\> 4 on the Fagerstrom Test for Nicotine Dependence) High caffeine dependence based on the Caffeine Dependence Questionnaire (\\> 30 on the Caffeine Dependence Questionnaire)\n* Currently experiencing a neurological disorder (e.g., stroke, Parkinson's, MS, etc.)\n* Exclusion for optional MRI visit:\n\nMetal in body that is ferromagnetic \u002F incompatible with MRI or other safety issues and indicated by screen Previous adverse reactions to sleep deprivation Illicit drug use as determined by participant self-report Alcohol in system at time of MRI overnight as determined participant self report Nicotine use in the last 3 months\n\nFor poor sleep group:\n\nTBI History of epilepsy or suspected seizure disorder.","62 Years",{"count":179,"type":22},180,[25],"The INSIGHT study is a multi-site clinical research program designed to examine how insomnia and symptoms of sympathetic hyperactivity impair sleep, cognition, and physiological restoration in warfighters, and to evaluate whether a wearable therapeutic device can improve these outcomes. Warfighters with a history of traumatic brain injury, post-traumatic stress disorder, or chronic operational stress commonly report disrupted sleep accompanied by manifestations of nocturnal sympathetic activation such as diaphoresis, palpitations, hyperarousal, and nightmares. These symptoms erode sleep quality, reduce cognitive performance, and undermine psychological resilience and operational readiness. Insomnia is two to three times more common in military populations than in civilians, and both TBI and PTSD independently elevate the risk for dysregulated autonomic tone. Excessive sympathetic activity during REM sleep disrupts the normally quiescent locus coeruleus state required for adaptive emotional processing and may contribute to the genesis of nightmares. Excessive sympathetic tone may also interfere with deep NREM-dependent glymphatic clearance, a recently discovered mechanism that supports cognitive restoration and metabolic waste removal. Yet, no study has comprehensively linked these physiological processes in warfighters or evaluated whether wearable-derived autonomic measures can meaningfully stratify insomnia phenotypes. The INSIGHT protocol addresses this gap through a two-phase design integrating multimodal biomarker collection, wearable technology validation, advanced imaging, and a randomized controlled intervention. Phase 1 enrolls 250 participants (50 healthy controls and 200 poor sleepers with or without PTSD and TBI) who undergo structured screening, cognitive testing, and detailed baseline assessments before completing a 2-week at-home data collection period. During this period, participants wear a suite of devices, including EEG headbands, ECG patches, PPG-based sensors, accelerometry rings, blood pressure devices, temperature sensors, and smartwatches, to capture autonomic activity, sleep architecture, cardiovascular and respiratory variability, movement, sudomotor activity, and circadian body temperature patterns. Ecological momentary assessments administered three times daily track fluctuations in sleep quality, mood, PTSD symptoms, and daytime functioning, while urine samples collected on the final three days allow for biochemical analysis of hormonal and sympathetic biomarkers. After the at-home period, all participants complete an overnight in-lab polysomnogram combined with fNIRS to measure sleep stages, autonomic dynamics, cerebral hemodynamics, and glymphatic signatures. A subset of participants also completes an optional overnight MRI with simultaneous EEG following controlled sleep deprivation, enabling state-of-the-art imaging of human glymphatic activity using the MAGNUS MRI platform. This optional visit provides unprecedented insight into how TBI, PTSD, and insomnia alter the physiology of sleep-dependent brain fluid dynamics. In Phase 2, all poor sleepers enter a double-blind, sham-controlled, 30-day randomized trial testing the therapeutic potential of the NightWare smartwatch. NightWare detects sympathetic surges during sleep through heart rate elevations and movement patterns and delivers brief haptic vibrations aimed at interrupting escalating autonomic arousal. Although originally cleared for nightmare treatment, its mechanism is well suited for SNH-related insomnia more broadly. Participants use the device daily while continuing EMA surveys, wearable monitoring, and cognitive assessments, generating rich physiological and behavioral data throughout the intervention. The primary goal is to determine whether reducing nocturnal sympathetic spikes leads to measurable improvements in sleep quality, autonomic stability, daytime functioning, and symptom burden. In parallel, Phase 2 data enable development of the Multi-Organ Autonomic Index of Sleep, an integrated biomarker model that combines neurological, cardiovascular, respiratory, and dermal signals to predict treatment response and classify insomnia subtypes.\n\nThe INSIGHT study will produce the most comprehensive dataset to date linking autonomic physiology, glymphatic function, sleep architecture, wearable-derived biomarkers, cognition, and clinical outcomes in warfighters. By identifying physiological signatures of sympathetic hyperarousal and determining whether a non-pharmacological wearable intervention can meaningfully improve sleep, INSIGHT directly supports Department of Defense priorities to enhance readiness, resilience, and long-term neurological health in service members. Wearable tools capable of monitoring and improving sleep outside the laboratory have the potential to transform both clinical care and operational performance, offering scalable and accessible approaches to restoring sleep and optimizing recovery.",[183,184,185,186,29,187],"Nightmare","Insomnia","PTSD","TBI","REM Behavior Disorder",[189,190,191,192,193,184,185,194],"Nightmares","Wearables","Intervention","Sleep quality","Hyperarousal","Healthy Participants","2026-04-27",{"date":197,"type":44},"2026-04-28",{"date":199,"type":22},"2026-06-01",{"date":201,"type":22},"2027-12",{"name":203,"class":204},"Uniformed Services University of the Health Sciences","FED",2,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":80},"100617199","phase-2-sleep-and-stress-study-100617199","NCT07315516","Sleep and Stress Study","The Effects of Natural Bioactive Compounds on Sleep and Stress: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Generally healthy adults aged 18 and over.\n* Able to provide informed consent.\n* Score of at least 14 on the Perceived Stress Scale (PSS).\n* Those with a sleep complaint with a frequency of at least 2 times per week(1)\n* Agree not to use other dietary supplements for sleep, depression, stress or anxiety other than the investigational product during entire study period.\n* Agree not to change current diet and\u002For exercise frequency or intensity during entire study period.\n* Agree to not participate in another clinical trial during the study period.\n\n  1. Sleep complaints are defined as difficulty initiating sleep, or difficulty maintaining sleep, or early-morning awakening with inability to return to sleep and causing distress or impairment in social, occupational, educational, academic, behavioural, or other important areas of functioning.)\n\nExclusion Criteria:\n\n* A WHO-5 Well-Being Index score ≤ 28\n* Those with severe sleep complaints (Insomnia Severity Index \\>21)\n* Taking prescribed sleep, depression or anxiety medication\n* Have a serious illness e.g. asthma, depression, anxiety disorder, bipolar disorder, insomnia, organic sleep disorders (i.e. sleep apnoea), neurological disorders such as MS, kidney disease, liver disease or heart conditions\n* Have an unstable illness e.g. diabetes and thyroid gland dysfunction\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years\n* Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin\n* Active smokers, nicotine use or drug (prescription or illegal substances) abuse\n* Chronic past and\u002For current alcohol use (\\>21 alcoholic drinks week)\n* Those consuming more than 500mg caffeine per day\n* Pregnant or lactating women\n* Allergic to any of the ingredients in active or placebo formula\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion",{"count":214,"type":22},240,[119],"The goal of this clinical trial is to learn if natural supplements (lavender oil, PEA, and OEA) work to improve sleep and reduce stress in adults with moderate stress levels and sleep difficulties. It will also learn about the safety of these natural supplements.\n\nThe main questions it aims to answer are:\n\n* Do these supplements improve sleep quality?\n* Do they reduce perceived stress levels?\n* Do they reduce anxiety symptoms?\n* What medical problems do participants have when taking these supplements?\n\nResearchers will compare three active treatment groups (lavender oil, PEA, Trpti which contains OEA) to a placebo (a look-alike capsule that contains no active ingredients) to see if these natural supplements work to improve sleep and reduce stress.\n\nParticipants will take 1 capsule (either active supplement or placebo) every day for 8 weeks and attend 2 clinic visits with a phone check in in between.",[29,151,218],"Anxiety",[220],"Sleep complaints","2026-04-22",{"date":223,"type":44},"2026-04-23",{"date":225,"type":44},"2026-04-07",{"date":227,"type":22},"2027-02",{"name":229,"class":230},"RDC Clinical Pty Ltd","INDUSTRY",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":239,"maxAge":18,"enrollmentInfo":240,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":80},"100609124","turkish-adaptation-of-a-sleep-screening-tool-for-pediatric-complex-chronic-conditions-100609124","NCT07210476","Turkish Adaptation of a Sleep Screening Tool for Pediatric Complex Chronic Conditions","Turkish Adaptation and Psychometric Evaluation of the Sleep Screening Tool for Children and Adolescents With Complex Chronic Conditions","SCAC","Inclusion Criteria:\n\nAge 1 month to 18 years At least one complex chronic condition (per 2014 CCC classification) Admission to a pediatric intensive care unit (PICU) Parents willing to participate Parents literate in Turkish\n\nExclusion Criteria:\n\nParents with insufficient Turkish language proficiency to complete study materials","1 Month",{"count":241,"type":22},330,"OBSERVATIONAL","This study aims to adapt the Sleep Screening Scale for Children and Adolescents with Complex Chronic Conditions (SCAC) into Turkish and test its reliability and validity for this population. Children and adolescents with complex chronic conditions (CCC) often have ongoing and multiple health problems. These children often face a high risk of sleep problems, but there are no screening tools in Turkish designed specifically for them.\n\nThe main goal is to confirm that the Turkish version of the SCAC is accurate and reliable. The study will also look at how common different types of sleep problems are in children with CCC, and how these problems are related to factors such as diagnosis, age, sex, and other medical conditions.\n\nAnother goal is to compare children's sleep at home with their sleep during a stay in the pediatric intensive care unit (PICU). The study will also examine how environmental factors (such as light and noise) and medical factors (such as pain, medications, and devices) affect sleep in the hospital. After discharge, sleep recovery will be followed for up to 3 months using sleep diaries and actigraphy (a wearable device that measures movement during sleep).",[245,246,29,247],"Chronic Conditions","Pediatric Intensive Care","Sleep",[249,97,250,251,252],"sleep","child","chronic disease","actigraphy","2026-04-16",{"date":255,"type":44},"2026-04-17",{"date":257,"type":44},"2026-03-12",{"date":259,"type":22},"2027-06",{"name":261,"class":51},"Marmara University",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":80},"100625542","evaluation-of-changes-in-sleep-efficiency-among-pic-du-midi-staff-between-nights-spent-at-home-and-nights-spent-in-the-workplace-under-high-altitude-conditions-100625542","NCT07423988","Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the Workplace Under High Altitude Conditions","Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Employees Between Nights Spent at Home (Without Increased Altitude) and Nights Spent in a Professional Environment Under High Altitude Conditions","ALTISOM","Inclusion Criteria:\n\nGroup \"with on-call night at high altitude at the Pic du Midi\":\n\n* Employed at the Pic du Midi for at least one month\n* Working nights at high altitude (at the Pic du Midi, altitude of 2877m) as part of their professional activity\n* Person affiliated with or covered by a social security scheme\n* Free, informed, and written consent signed by the participant and the investigator\n\nNight group \"without on-call night at high altitude\":\n\n* Employed at the Pic du Midi for at least one month\n* Not working nights at high altitude (at the Pic du Midi, altitude of 2877m) as part of their professional activity\n* Person affiliated with or covered by a social security scheme social\n* Free, informed and written consent signed by the participant and the investigator\n\nExclusion Criteria:\n\n* For all participants:\n* History of cardiovascular disease\n* Use of cardiovascular\u002Fpsychotropic medication\n* Participant under legal guardianship or other protective regime (guardianship, curatorship)\n* Pregnant or breastfeeding woman\n* French language proficiency insufficient to complete the questionnaires",{"count":271,"type":22},32,[25],"Sleep organization and cardiorespiratory parameters are disrupted in extreme conditions such as high altitude. The pathophysiology of medical problems related to acute high-altitude exposure is partially understood, but sleep quality indicators are very rarely measured under these conditions. This lack of information is even more pronounced among employees subjected to cyclical exposure to high-altitude hypoxic stress, as is the case for the employees at the Pic du Midi. These 32 employees regularly report to their occupational physician difficulties in managing their sleep disorders, struggling to distinguish symptoms from objective changes in their sleep cycles. Among them, 13 are on call at the summit of the Pic du Midi (2,877 m), while 19 work there during the day and return home to a lower altitude at night to sleep. The investigators also wish to measure structural changes in sleep and its cardiorespiratory parameters using polysomnography in these 13 employees, comparing nights spent at home at normal altitude with those spent at the summit of the Pic du Midi. These changes will also be compared to those of a group of 19 employees who do not sleep at high altitude..",[29],[249,276,97,277],"high altitude","cardiorespiratory parameters",{"date":279,"type":44},"2026-04-08",{"date":281,"type":44},"2026-03-23",{"date":283,"type":22},"2027-02-28",{"name":285,"class":51},"University Hospital, Toulouse",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":80},"100629240","effects-of-telerehabilitation-based-dual-task-exercises-on-balance-fall-risk-cognitive-function-and-sleep-quality-in-geriatric-individuals-100629240","NCT07472101","Effects of Telerehabilitation-Based Dual-Task Exercises on Balance, Fall Risk, Cognitive Function, and Sleep Quality in Geriatric Individuals","The Effects of Dual-Task Exercises Performed Through Telerehabilitation on Balance, Falls, Cognitive Function, and Sleep Quality in Geriatric Individuals: A Randomised Control Trial","Inclusion Criteria:\n\nParticipants aged 65 to 74 years.\n\nBerg Balance Scale (BBS) score between 41 and 56.\n\nTinetti Performance Oriented Mobility Assessment (POMA) score between 19 and 23.\n\nMini-Mental State Examination (MMSE) score between 18 and 30.\n\nIndependent in activities of daily living.\n\nAble to walk without assistive devices.\n\nCapable of using video call applications for telerehabilitation sessions.\n\nExclusion Criteria:\n\nParticipants younger than 65 years.\n\nIndividuals with cardiovascular diseases.\n\nAmputees.\n\nIndividuals with severe cognitive impairment.\n\nIndividuals with significant visual or hearing impairments.\n\nIndividuals without internet access.\n\nIndividuals unable to use video call applications for telerehabilitation sessions.","74 Years",{"count":295,"type":22},60,[25],"The purpose of this study is to investigate the effects of dual-task exercises-which simultaneously target cognitive and motor functions-delivered via telerehabilitation on fall risk, balance, cognitive functions, and sleep quality in geriatric individuals.Aging is often associated with balance disorders, increased fall risk, cognitive decline, and impaired sleep quality, all of which significantly impact the quality of life in the elderly. Dual-task interventions require individuals to perform physical and cognitive tasks concurrently, aiming to improve sensorimotor control and enhance balance strategies under cognitive load.This study utilizes telerehabilitation as a cost-effective and sustainable solution to facilitate access to healthcare services, providing a remote alternative to face-to-face rehabilitation. The research aims to demonstrate that dual-task exercises performed through telerehabilitation can contribute to functional recovery, reduce the fear of falling, and increase the safe mobility capacity of geriatric individuals.",[299,300,29],"Aging","Balance Control in Elderly",[302,303,304,305,306],"telerehabilitation","dual-task exercise","balance","cognitive function","sleep quality","2026-03-10",{"date":309,"type":44},"2026-03-16",{"date":311,"type":44},"2026-02-02",{"date":313,"type":22},"2026-07-02",{"name":315,"class":51},"Bulent Ecevit University",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":205},"100626222","assessment-of-the-association-between-sleep-disorders-detected-by-a-simplified-questionnaire-and-cardiovascular-diseases-100626222","NCT07432828","Assessment of the Association Between Sleep Disorders Detected by a Simplified Questionnaire and Cardiovascular Diseases","Assessment of the Association Between Sleep Disorders Detected by a Simplified Questionnaire and Cardiovascular Diseases: a Prospective Study in Cardiology Consultations","CARDIOSOM","Inclusion Criteria - Patient :\n\n* Adult patients (≥18 years old) consulting in cardiology.\n* Ability to complete the questionnaire.\n* No objection\n\nInclusion Criteria - Cardiologist:\n\nCardiologists who participated in CARDIOSOM and who conduct cardiology consultations that include a systematic or non-systematic assessment of their patients' sleep quality (duration, regularity, insomnia, sleepiness, suspected obstructive sleep apnea (OSA)) and whether or not suspected sleep disorders in patients are treated.\n\nExclusion Criteria - Patient :\n\n* Active treatment for a severe sleep disorder (severe sleep apnea under CPAP (Continuous Positive Airway Pressure) or orthotic device, narcolepsy, chronic insomnia being treated)\n* Refusal to participate\n\nExclusion Criteria - Cardiologist :\n\nNot applicable",{"count":325,"type":22},1500,"The goal of this observational study is to validate a simplified questionnaire, adapted for routine clinical use, to quickly detect sleep disorders in patient during a cardiology consultation.\n\nTwo questionnaires were developed for this project. The first is patient-oriented: a prospective, multicentre, national observational registry based on a patient questionnaire designed to quickly detect sleep disorders during a cardiology consultation.\n\nThe second is aimed at treating cardiologists: this is a simple impact survey designed to assess changes in the practices of cardiologists who participated in CARDIOSOM.",[29,328],"Cardio Vascular Disease",[330,331,332],"sleep disorders","risk of cardiovascular conditions","simplified questionnaire","2026-02-19",{"date":335,"type":44},"2026-02-25",{"date":337,"type":44},"2026-01-15",{"date":339,"type":22},"2027-01",{"name":341,"class":51},"French Cardiology Society",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":357,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":4},"100625694","sleep-hygiene-education-to-improve-sleep-in-chronic-migraine-and-back-pain-100625694","NCT07425964","Sleep Hygiene Education to Improve Sleep in Chronic Migraine and Back Pain","Kan Uddannelse i søvnhygiejne Forbedre søvnkvalitet for Patienter Med Kroniske Smerter?","Inclusion Criteria:\n\n* Chronic back pain (average pain VAS ≥ 3) AND\u002FOR Migraine (migraine or tension headaches ≥15 days per month with ≥8 days being migraine)\n* Lasting ≥3 months\n* Adults ≥18 years old\n* Read, speak, and understand Danish\n* Willing to implement sleep hygiene for four weeks\n* Digital competencies (sufficient to answer questionnaires online)\n\nExclusion Criteria:\n\n* Pregnancy\n* Drug addiction, defined as the use of cannabis, opioids, or other drugs\n* Malignant comorbidity (e.g., cancer)\n* Neurological conditions affecting cognition (e.g., multiple sclerosis, epilepsy, dementia, previous stroke\u002Ftransient cerebral ischemia)\n* Intake of acute headache medication on ≥15 days\u002Fmonth for simple analgesics\u002FNSAIDs or ≥10 days\u002Fmonth for triptans, ergotamine, opioids, or combinations thereof over 3 months.\n* Use of unstable sleep-modulating pharmacological treatment (e.g., melatonin, tricyclic antidepressants)\n* Diagnosed sleep disorder (e.g., insomnia, narcolepsy, sleep apnoea)\n* Night-shift work\n* Initiation of any new therapy during the study period\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",{"count":350,"type":22},100,[25],"The goal of this clinical trial is to learn whether sleep hygiene education can improve sleep quality and reduce pain in adults with migraine and\u002For chronic lower back pain. Poor sleep is common in people with chronic pain and may worsen symptoms. Improving sleep may help break this cycle.\n\nThe main questions this study aims to answer are:\n\n1. Does a four-week sleep hygiene education program improve sleep quality?\n2. Does improved sleep lead to reduced pain intensity and changes in pain sensitivity?\n\nThis study does not include a comparison group. Each participant serves as their own comparison by completing the same tests before and after the sleep hygiene program.\n\nParticipants will:\n\n* Attend two study visits lasting 30-60 minutes, one at the beginning and one after four weeks\n* Complete questionnaires about sleep, pain, mood, and quality of life at both visits\n* Undergo pain sensitivity testing using light pinprick stimulations on the forearm\n* Receive individual sleep hygiene education and written materials to use at home for four weeks\n* Complete a short weekly online check-in about sleep habits and pain\n* Complete a three-month follow-up questionnaire about sleep habits, sleep quality, and pain",[354,355,356,29],"Migraine Disorder","Low Back Pain","Chronic Pain",[358,359,360],"Sleep Quality","Sleep Hygiene","Pain Sensitivity","2026-02-16",{"date":363,"type":44},"2026-02-23",{"date":365,"type":22},"2026-02",{"date":367,"type":22},"2028-12",{"name":369,"class":51},"Aalborg University",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":80},"100606211","the-effect-of-avnace-ezze-on-sleep-improvement-100606211","NCT07172607","The Effect of Avnace eZZe on Sleep Improvement","Inclusion Criteria:\n\n* Male or female age 18 years or older;\n* Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) criteria for Insomnia Disorder;\n* Regular bedtime, between 21:00 and 01:00 and regular wake time;\n* Insomnia Severity Index (ISI) score ≥15;\n* All medications or interventions for insomnia, mental or physical disorders must have been stable for at least four weeks prior to screening, and participants had to be willing to maintain a stable regimen throughout the study;\n* No consumption of sleep or stress-related supplements for at least four weeks prior to screening;\n* Willing and able to comply with all aspects of the protocol.\n\nExclusion Criteria:\n\n* A current diagnosis of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder;\n* Depressive symptoms at screening were considered significantly severe with a PHQ-9 score \\> 14\n* Anxiety symptoms at screening were considered significantly severe with a GAD-7 score \\> 15;\n* Females who are breastfeeding or pregnant;\n* Females of childbearing potential who are not practicing acceptable pregnancy prevention methods (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically.);\n* Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or habitually consumes caffeine-containing beverages after 18:00 and is unwilling to forego caffeine after 18:00 for the duration of his\u002Fher participation in the study;\n* History of drug or alcohol dependency or abuse within approximately the previous 2 years;\n* Current evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal, neurological, or psychiatric disease or malignancy or chronic pain that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments;\n* Scheduled for major surgery during the study;\n* Participants known to be allergic to any components of the product.",{"count":377,"type":22},75,[25],"This study aims to examine the effectiveness of Avance eZZe drink with liposomal technology in improving sleep quality. Participants will be randomly assigned to either the placebo group, Avance eZZe drink group, and Avance eZZe drink without liposomal group, with 25 participants in each group. On the day of the experiment (day 0), participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them 1 hour before sleep daily for 28 days. Follow-up assessments will be conducted in the day-1, day-14 and day-28, participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions.",[29,381],"Anxiety Depression Disorder",{"date":383,"type":44},"2026-02-04",{"date":385,"type":44},"2025-09-09",{"date":387,"type":22},"2026-06-30",{"name":389,"class":230},"TCI Co., Ltd.",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":400,"conditions":401,"keywords":404,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":80},"100621914","effect-of-sleeping-posture-guidance-on-sleep-quality-in-patients-with-rotator-cuff-syndrome-100621914","NCT07376811","Effect Of Sleeping Posture Guidance On Sleep Quality In Patients With Rotator Cuff Syndrome","Effect Of Sleeping Posture Guidance On Sleep Quality In Patients With Rotator Cuff Syndrome Undergoing Physical Therapy: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Clinical and\u002For radiological diagnosis of Rotator Cuff Syndrome (RCS).\n* Presence of shoulder pain for at least 3 months (chronic pain).\n* Patients aged between 18 and 65 years.\n* Patients referred for conservative physical therapy treatment.\n* Ability to understand and answer the assessment questionnaires (PSQI, MSQ, ASES, and VAS).\n* Voluntarily signing the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* History of surgical procedures on the affected shoulder.\n* Presence of fractures or recent acute trauma in the shoulder or upper limb.\n* Associated neurological disorders, inflammatory systemic diseases (e.g., Rheumatoid Arthritis), or adhesive capsulitis (frozen shoulder).\n* Previous diagnosis of primary sleep disorders unrelated to pain (e.g., severe obstructive sleep apnea) already under clinical treatment.\n* Recent history of corticosteroid injections in the shoulder (within the last 3 months).",{"count":398,"type":22},64,[25],"This study investigates sleep quality in patients with Rotator Cuff Syndrome (RCS) undergoing physical therapy treatment. Existing literature presents a gap regarding longitudinal studies evaluating the impact of physical therapy and different sleeping positions on sleep quality within this specific population. The central hypothesis is that physical therapy, combined with guidance on the best sleeping positions, reduces pain, improves shoulder function, and consequently promotes an improvement in sleep quality for RCS patients over time. The justification for this research lies in the need to better understand the relationship between physical therapy and sleep quality in RCS patients, aiming for the development of more effective and less invasive interventions. Previous studies have demonstrated that chronic pain, a common symptom of RCS, is intrinsically linked to sleep disturbances, which can lead to deleterious effects such as dopamine reduction, alterations in the descending pain modulation system, and central sensitization. Improvements in sleep quality have been observed after surgical procedures such as shoulder arthroscopy and arthroplasty, often associated with improved function and pain reduction. Thus, this study seeks to longitudinally evaluate whether physical therapy is capable of promoting a sustained improvement in sleep quality for patients with RCS",[402,403,29],"Rotator Cuff Syndrome","Rotator Cuff Injury",[405,306,406,407,408,409,410],"rotator cuff syndrome","sleeping position","physical therapy","randomized controlled trial","shoulder pain","rehabilitation","2026-01-25",{"date":413,"type":44},"2026-01-29",{"date":415,"type":22},"2026-03-01",{"date":417,"type":22},"2029-11-01",{"name":419,"class":51},"Federal University of São Paulo",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":88,"sex":17,"minAge":427,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":435,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":205},"100616127","pilot-study-of-negative-pressure-neck-therapy-npnt-100616127","NCT07301567","Pilot Study of Negative Pressure Neck Therapy (NPNT)","A Proof-of-concept Pilot Study to Determine the Safety and Effectiveness of the Negative Pressure Neck Therapy (NPNT) in Healthy Participants.","Inclusion Criteria:\n\n* Body mass index ≤42 kg\u002Fm2\n* Able to speak, read, and write English\n\nExclusion Criteria:\n\n* Known sleep disorder such as Obstructive Sleep Apnea (OSA), narcolepsy, restless leg syndrome, idiopathic hypersomnolence or chronic insomnia\n* No previous surgery, injury, or radiation to the neck\n* Excessive hair or beard in the area of the neck, and\u002For unwillingness to shave that area for the duration of this study\n* Inflammatory skin condition, such as acne or eczema in the neck area\n* Known silicone allergy\n* Night shift work because of irregular sleep-wake cycles\n* Excessive alcohol intake, defined as that leading to interference with work, home life, or the ability to optimally perform normal everyday duties and tasks\n* Use of illicit drugs currently or within the past 5 years\n* Serious pulmonary disease\n* Use of home oxygen or oxygen saturation \\\u003C94%\n* Cancer that has been in remission for less than one year\n* Previous surgery for peripheral arterial disease","19 Years",{"count":429,"type":22},10,[25],"Obstructive sleep apnea (OSA) is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. This pilot study will evaluate the Safety and Efficacy of Negative Pressure Neck Therapy (NPNT) in up to 10 healthy participants. Participants will undergo 2 separate home sleep apnea tests (HSAT) approximately 1 week apart and will be randomly assigned to wear the NPNT device at either night 1 or night 2 of HSAT. Participation will include 5 on-site visits and 1 phone call over approximately 1 month.",[433,434,29],"Obstructive Apnea","Sleep Apnea Syndrome, Obstructive",[436,437,438],"sleep apnea","Obstructive sleep apnea","sleep disordered breathing","2025-12-10",{"date":441,"type":44},"2025-12-24",{"date":443,"type":22},"2026-01",{"date":77,"type":22},{"name":446,"class":51},"University of British Columbia",{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":453,"minAge":18,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":4},"100613927","effects-of-ultrasound-guided-stellate-ganglion-block-and-transcutaneous-auricular-vagus-nerve-stimulation-on-sleep-quality-after-radical-mastectomy-for-breast-cancer-100613927","NCT07272954","Effects of Ultrasound-Guided Stellate Ganglion Block and Transcutaneous Auricular Vagus Nerve Stimulation on Sleep Quality After Radical Mastectomy for Breast Cancer","Inclusion Criteria:\n\n* aged 18-80 years who underwent radical surgery for breast cancer\n* ASA I-III\n\nExclusion Criteria:\n\n* 1\\. Patients with coagulation dysfunction;\n* Patients with suspected regional infection leading to severe nerve damage in the affected limb;\n* Patients with congenital heart disease, coronary artery disease, myocardial infarction, severe cardiac conduction block, or those with implanted cardiac pacemakers;\n* Patients with severe neurological disorders such as cerebral infarction, cerebral hemorrhage, or stroke;\n* Patients with pain, lesions, infections, or unresolved external ear trauma in the area near the external ear;\n* Patients with severe mental illness or a history of substance abuse related to analgesics or psychiatric medications;\n* Patients with allergies to local anesthetics such as lidocaine or ropivacaine, as well as to general anesthetics;\n* Patients and their families who refuse surgical anesthesia and those unable to complete the survey questionnaire.","FEMALE","80 Years",{"count":456,"type":22},136,[25],"This study aims to design a prospective, randomized, controlled, dual-center, non-inferiority trial to compare the effects of ultrasound-guided sympathetic ganglion block (SGB) and transcutaneous auricular vagus nerve stimulation (taVNS) on sleep quality following radical mastectomy for breast cancer. The objective is to explore whether non-invasive neuromodulation for sleep is non-inferior to invasive neuromodulation. Participants will be randomly assigned to receive either SGB or taVNS treatment. Sleep quality will be assessed using an actigraphy device and sleep scales within four days post-surgery, and the incidence of sleep disturbances will be followed up within 30 days post-surgery.",[29],[461],"taVNS","2025-12-08",{"date":464,"type":44},"2025-12-09",{"date":466,"type":22},"2026-12-01",{"date":468,"type":22},"2029-12-01",{"name":470,"class":51},"Affiliated Hospital of Jiaxing University",{"id":472,"slug":473,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":453,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":482,"conditions":483,"keywords":487,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":205},"100604062","peroneal-electrical-nerve-stimulation-in-pregnancy-for-restless-legs-syndrome-100604062","NCT07144631","Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome","PENS-P: Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome (RLS)","PENS-P","Inclusion Criteria:\n\n* Age ≥18 years\n* Pregnant individuals between 21 and 26 weeks' gestation at enrollment\n* Singleton pregnancy without known fetal anomalies\n* Confirmed clinical diagnosis of Restless Legs Syndrome (RLS) according to International Restless Legs Syndrome Study Group (IRLSSG) criteria, confirmed by a sleep medicine specialist to exclude RLS mimics\n* Able and willing to provide informed consent\n* Able and willing to comply with study procedures, including device usage, questionnaires, adherence diaries, and follow-up assessments up to 3 months postpartum\n\nExclusion Criteria:\n\nPregnancy-related:\n\n* History of preterm labor\n* Known fetal anomalies identified prior to enrollment\n\nNeurological and neuromuscular disorders:\n\n* Pre-existing neuromuscular disorders affecting balance or gait\n* Severe peripheral neuropathy involving the lower legs\n* Epilepsy or history of seizures\n\nCardiovascular and circulatory conditions:\n\n* History of deep vein thrombosis (DVT)\n* Circulatory conditions contraindicating peroneal nerve stimulation (PNS) device use\n\nDermatological conditions:\n\n* Skin conditions at device application sites\n* Known allergy to device materials\n\nOther sleep disorders:\n\n• Inadequately treated severe primary sleep disorders other than RLS (e.g., untreated severe sleep apnea, severe insomnia unrelated to RLS)\n\nDevice and treatment experience exclusions (based on RESTFUL trial criteria):\n\n* Prior use of the study device or any neurostimulation device for RLS treatment\n* Presence of active medical implants (e.g., pacemakers, spinal cord stimulators)\n\nOther medical conditions:\n\n* Participants undergoing dialysis treatment\n* Severe psychiatric conditions (e.g., bipolar disorder, psychosis, severe anxiety or depression) that may interfere with adherence or accurate symptom reporting\n* Any condition deemed by investigators to pose safety risks or impede participation\n\nOther exclusions:\n\n* Unable or unwilling to operate the device safely and independently\n* Unable to participate reliably in follow-up assessments or complete self-reported diaries",{"count":480,"type":22},15,[25],"The goal of this study is to evaluate whether peroneal electrical nerve stimulation (PNS) using the TOMAC™ device is a feasible, acceptable, and safe non-pharmacologic intervention for managing Restless Legs Syndrome (RLS) during pregnancy. This pilot study will also collect preliminary information on symptom relief, sleep quality, and maternal-fetal safety associated with device use.\n\nThe main questions the study aims to answer are:\n\nIs TOMAC™ PNS a feasible and acceptable intervention for RLS in pregnant individuals? Are there any maternal, fetal, or neonatal safety concerns with PNS use during pregnancy? What are the patterns of adherence, tolerance, and usability of the TOMAC™ device in this population?\n\nParticipants will:\n\nUse a non-invasive TOMAC™ peroneal nerve stimulator during 30-minute sessions as needed, for 8 weeks.\n\nComplete questionnaires assessing feasibility, acceptability, symptom severity, and sleep quality (including AIM, IAM, FIM, IRLS, PGI-I, PSQI, ESS, FOSQ, and MOS-II).\n\nWear an actigraphy monitor to collect objective sleep data at baseline and at 4 weeks.\n\nAttend scheduled follow-up visits and phone check-ins for maternal vital signs, uterine contraction and fetal monitoring, and neonatal outcome assessment.\n\nThis is a prospective, open-label, single-arm pilot study enrolling 15 pregnant participants between 21 and 26 weeks' gestation. Findings will provide the first dataset on the feasibility, acceptability, and safety of TOMAC™ PNS in pregnancy and inform the design of a future randomized controlled trial.",[484,485,486,29],"Restless Leg Disorder","Restless Leg Syndrome (RLS)","Pregnancy",[488,486,489,490,491,492],"Restless Legs Syndrome","Sleep Disorders in Pregnancy","Maternal Sleep Health","Peroneal Nerve Stimulation","Neuromodulation","2025-11-10",{"date":495,"type":44},"2025-11-12",{"date":497,"type":44},"2025-10-15",{"date":499,"type":22},"2026-10-31",{"name":501,"class":51},"Rhode Island Hospital",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":80},"100599540","sleep-promoting-properties-of-a-botanical-extract-in-a-population-complaining-from-non-restorative-sleep-nrs-100599540","NCT07085819","Sleep Promoting Properties of a Botanical Extract in a Population Complaining From Non-Restorative Sleep (NRS)","A Prospective, Randomized, Double Blind, Placebo Controlled Study To Evaluate The Effects Of Ashwagandha (Withania Somnifera,Ws) Root Plus Leaf Aqueous Extract On Quality Of Sleep In Subjects With Non-Restorative","Inclusion Criteria:\n\n1. Be able to give written informed consent.\n2. Be between 18 and 65 years, inclusive.\n3. Self-reported unrefreshing sleep despite sufficient sleep duration for at least three nights a week over a one-month period.\n4. Have a RSQ-W total score of ≤50 at screening.\n5. TSH values between 0.27 - 4.20 miU\u002FL\n6. Is in general good health, as determined by the investigator.\n7. Willing to consume the Study Product daily for the duration of the study.\n\nExclusion Criteria:\n\n1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and\u002For currently breastfeeding.\n2. Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:\n\n   1. Complete abstinence from intercourse two weeks prior to administration of the Study Product, throughout the clinical study, until the completion of follow-up procedures or for two weeks following discontinuation of the Study Product in cases where Participant discontinues the study prematurely. (Participants utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).\n   2. Has a male sexual partner who is surgically sterilized prior to the Screening Visit and is the only male sexual partner for that Participant.\n   3. Sexual partner(s) is\u002Fare exclusively female.\n   4. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), tubal ligation, or contraceptive pill. The Participant must be using this method for at least one week prior to and one week following the end of the study.\n   5. Use of any intrauterine device (IUD) or contraceptive implant. The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.\n3. Has a score ≥10 on Patient Health Questionnaire 8 item (PHQ-8)\n4. Has a score ≥10 on Athens Insomnia Scale (AIS)\n5. Participants at a high risk of sleep apnoea as determined by Berlin questionnaire\u002FScore \\>5 for sleep apnoea.\n6. High caffeine intake, \\>400mg\u002Fday\n7. Has a history of drug and\u002For alcohol abuse at the time of enrolment.\n8. Has food allergies or other issues with foods that would preclude intake of the Study Products.\n9. Is an active smoker or user of nicotine products, or with a history of cigarettes smoking, tobacco or nicotine product use in the last 6 months.\n10. Has undertaken shift work within the last three months or plans to undertake shift work during the study.\n11. Travel across three time zones in the two months prior to screening or plans to travel across time zones during intervention.\n12. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:\n\n    1. Diagnosed gastrointestinal disease.\n    2. Respiratory disorders\n    3. Seizure disorders\n    4. Type 1 or 2 diabetes mellitus\n    5. Thyroid disorders\n    6. Uncontrolled hypertension\n    7. Cardiovascular disease\n    8. Immunocompromised health conditions\n13. Current or recent (in the 12 weeks prior to screening) use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:\n\n    1. Barbiturates, anticonvulsants, benzodiazepines, neuroleptics\n    2. Hypnotics\n    3. Melatonin\n14. Current or recent (in the 4 weeks prior to screening) use of prohibited nutritional or non-nutritional supplements, including:\n\n    1. Herbal sleep aid supplements (St. John's Wort, Ginkgo-biloba, kava kava)\n    2. Ashwagandha\n    3. Caffeine supplements\n15. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.\n16. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.",{"count":510,"type":22},160,[25],"The goal of this clinical trial is to evaluate the effect of the Botanical Extract in improving sleep symptoms of nonrestorative sleep (NRS) in healthy adults. The main question it aims to answer is\n\n• Does the Botanical Extract improve sleep quality and reduce symptoms of nonrestorative sleep (NRS)? Researchers will compare the Botanical Extract to a placebo to see if it works.\n\nParticipants will:\n\n* Take one of 3 doses of the Botanical Extract (125 mg\u002Fday, 250mg\u002Fday ,500mg\u002Fday) or a placebo every day for 8 weeks.\n* Visit the clinic four times for checkups and tests and receive three follow-up phone calls.",[514,29],"Non Restorative Sleep",[192,516,517,518],"Attention","Focus","Actigraph","2025-08-25",{"date":521,"type":44},"2025-08-26",{"date":523,"type":44},"2025-07-15",{"date":525,"type":22},"2025-12",{"name":527,"class":230},"Kerry Group P.L.C",{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":88,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":535,"targetDuration":537,"studyType":242,"phases":4,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":4},"100594477","the-correlation-between-sleep-quality-and-sleep-aid-use-and-dietary-patterns-100594477","NCT07019948","The Correlation Between Sleep Quality and Sleep Aid Use and Dietary Patterns","The Correlation Between Sleep Quality and Sleep Aid Use and Dietary Patterns of Medical Staff in Emergency and Critical Care Departments","Inclusion Criteria:\n\n* Medical staff who have obtained the qualification certificate of doctors and nurses through practice registration\n* Working in the emergency and critical care departments for more than 1 year\n* No serious physical disease and psychiatric history\n* be able to communicate in Chinese\n\nExclusion Criteria:\n\n* Interns, students or trainees\n* The last six consecutive months of sick leave, maternity leave, out of the learner\n* Non-night shift workers",{"count":536,"type":22},378,"1 Day","In this study, medical staff in emergency and critical care departments were investigated. It was assumed that the use of sleep aids and dietary patterns affected their sleep quality. The structural equation model was used to analyze the status of sleep quality of medical staff in emergency and critical care departments, and to explore the effects of sleep aids and dietary patterns on sleep quality and its mechanism.\n\n( 1 ) Is the overall sleep quality of medical staff in emergency and critical departments poor ( 2 ) Do medical staff with poor sleep quality in acute and critical departments use sleep aids more frequently ( 3 ) Is there a correlation between sleep quality and certain dietary patterns among medical staff in emergency and critical care departments ( 4 ) Are there significant differences in dietary choices among medical staff in emergency and critical departments using sleep aids",[29],[306,541,542,543,544],"Sleep disorders","Sedative-hypnotic drugs","Dietary pattern","Clinical medical staff","2025-07-06",{"date":547,"type":44},"2025-07-10",{"date":523,"type":22},{"date":550,"type":22},"2026-04-30",{"name":552,"class":51},"Wei XIA, PhD"]